A detailed history of Sei Investments CO transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Sei Investments CO holds 38,840 shares of TGTX stock, worth $690,963. This represents 0.0% of its overall portfolio holdings.

Number of Shares
38,840
Holding current value
$690,963
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 07, 2024

BUY
$13.02 - $21.3 $505,696 - $827,292
38,840 New
38,840 $590,000
Q2 2023

Aug 11, 2023

BUY
$15.48 - $35.0 $2.54 Million - $5.75 Million
164,243 Added 283.89%
222,097 $5.52 Million
Q1 2023

May 12, 2023

BUY
$10.23 - $19.34 $591,846 - $1.12 Million
57,854 New
57,854 $870,000
Q1 2022

May 13, 2022

SELL
$7.81 - $20.45 $223,459 - $585,115
-28,612 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$15.2 - $35.51 $288,207 - $673,305
18,961 Added 196.47%
28,612 $544,000
Q3 2021

Nov 12, 2021

SELL
$21.78 - $40.45 $344,559 - $639,919
-15,820 Reduced 62.11%
9,651 $321,000
Q2 2021

Aug 06, 2021

SELL
$32.5 - $48.96 $686,465 - $1.03 Million
-21,122 Reduced 45.33%
25,471 $988,000
Q1 2021

May 12, 2021

BUY
$41.61 - $54.3 $643,290 - $839,478
15,460 Added 49.66%
46,593 $2.32 Million
Q4 2020

Feb 08, 2021

BUY
$25.27 - $54.9 $212,444 - $461,544
8,407 Added 36.99%
31,133 $1.62 Million
Q3 2020

Nov 06, 2020

SELL
$18.49 - $27.24 $65,306 - $96,211
-3,532 Reduced 13.45%
22,726 $608,000
Q2 2020

Aug 11, 2020

BUY
$8.9 - $21.84 $233,696 - $573,474
26,258 New
26,258 $512,000
Q3 2018

Nov 08, 2018

SELL
$5.15 - $14.0 $339 - $924
-66 Closed
0 $0
Q2 2018

Aug 03, 2018

BUY
$12.5 - $15.0 $275 - $330
22 Added 50.0%
66 $1,000
Q3 2017

Nov 06, 2017

BUY
$10.0 - $12.7 $440 - $558
44
44 $1,000

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $2.58B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Sei Investments CO Portfolio

Follow Sei Investments CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sei Investments CO, based on Form 13F filings with the SEC.

News

Stay updated on Sei Investments CO with notifications on news.